# The Endocannabinoid System in Obsessive-Compulsive Disorder: A Scoping Review. > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/endocannabinoid-system-ocd-research-scoping-review/ > **Published:** 2026-03-24T10:07:50-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:41:05-04:00 > **Clinical Summary:** Explore the latest endocannabinoid system OCD research highlighting preclinical findings and gaps in human studies for treatment-resistant OCD. --- CED Clinical Relevance  #56Monitored Relevance  Early-stage or contextual signal requiring further evidence before action. 🔬 Evidence Watch  |  CED Clinic Ocd[Endocannabinoid System](https://cedclinic.com/endocannabinoid-system-fear-extinction/)Treatment-ResistantPreclinicalScoping Review Journal Neuroscience and biobehavioral reviews Study Type Clinical Study Population Human participants Why This Matters With 40% of OCD patients failing to respond to standard treatments, understanding the endocannabinoid system’s role could inform new therapeutic approaches. This scoping review synthesizes the limited but consistent preclinical evidence suggesting ECS modulation affects compulsive behaviors. Clinical Summary This scoping review identified only 13 eligible studies examining the [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/) in OCD, with 12 being preclinical animal studies and one incorporating both animal and human data. Preclinical findings consistently showed that enhancing endocannabinoid system activity reduced compulsive and habitual behaviors, while inhibiting ECS activity worsened these symptoms. The review highlights a significant gap in human research, with virtually no clinical studies directly examining ECS function in OCD patients. The limited evidence base underscores how early we are in understanding this potential therapeutic target. Dr. Caplan’s Take “I see patients with treatment-resistant OCD regularly, and while these preclinical findings are intriguing, we cannot make clinical recommendations based on animal models alone. The near-absence of human data means we’re still years away from evidence-based cannabis protocols for OCD.” Clinical Perspective 🧠 Clinicians should recognize that cannabis for OCD remains experimental with no established dosing protocols or safety data in this population. Patients asking about cannabis for OCD should be counseled about the lack of human evidence while maintaining focus on proven treatments like SSRIs and exposure therapy. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20The%20Endocannabinoid%20System%20in%20Obsessive-Compulsive%20Disorder%3A%20A%20Scoping%20Review.%20%40drcaplan&url=https%3A//pubmed.ncbi.nlm.nih.gov/41871777/)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//pubmed.ncbi.nlm.nih.gov/41871777/)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20The%20Endocannabinoid%20System%20in%20Obsessive-Compulsive%20Disorder%3A%20A%20Scoping%20Review.%20--%20via%20%40drcaplan.bsky.social%20https%3A//pubmed.ncbi.nlm.nih.gov/41871777/)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://pubmed.ncbi.nlm.nih.gov/41871777/](https://pubmed.ncbi.nlm.nih.gov/41871777/) Table of Contents - [FAQ](#FAQ)[What percentage of OCD patients don’t respond to current treatments?](#What_percentage_of_OCD_patients_don8217t_respond_to_current_treatments) - [How does the endocannabinoid system affect OCD symptoms according to preclinical studies?](#How_does_the_endocannabinoid_system_affect_OCD_symptoms_according_to_preclinical_studies) - [Is there enough human clinical data to support cannabis use for OCD treatment?](#Is_there_enough_human_clinical_data_to_support_cannabis_use_for_OCD_treatment) - [Should clinicians recommend cannabis products for treatment-resistant OCD patients?](#Should_clinicians_recommend_cannabis_products_for_treatment-resistant_OCD_patients) - [What role does the endocannabinoid system play in OCD pathophysiology?](#What_role_does_the_endocannabinoid_system_play_in_OCD_pathophysiology) - [Related](#Related) ## FAQ #### What percentage of OCD patients don’t respond to current treatments? According to this research, approximately 40% of individuals with obsessive-compulsive disorder do not respond adequately to current standard interventions, including pharmacotherapy and psychotherapy. This significant treatment gap highlights the urgent need for alternative therapeutic approaches for treatment-resistant OCD patients. #### How does the endocannabinoid system affect OCD symptoms according to preclinical studies? Preclinical findings consistently demonstrated that enhancing endocannabinoid system (ECS) activity reduces compulsive and habitual behaviors associated with OCD. Conversely, inhibiting ECS activity appears to worsen these behaviors, suggesting the endocannabinoid system may play a protective role against [OCD symptoms](https://cedclinic.com/cannabinoids-for-tic-disorders-ocd/). #### Is there enough human clinical data to support cannabis use for OCD treatment? Currently, there is insufficient human clinical evidence to support [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) for OCD treatment. This scoping review identified only one study that included human samples among 13 eligible studies, with the remaining 12 being preclinical animal studies, indicating a significant gap in human research. #### Should clinicians recommend cannabis products for treatment-resistant OCD patients? Based on this evidence review, clinicians should exercise caution and avoid recommending cannabis products for OCD treatment at this time. While preclinical data shows promise, the lack of robust human [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) and the “monitored relevance” classification indicate this remains early-stage evidence requiring further validation. #### What role does the endocannabinoid system play in OCD pathophysiology? The endocannabinoid system, which regulates physiological, behavioral, and cognitive processes, is suggested to contribute to OCD pathophysiology, though its exact role remains largely unexplored. Current evidence suggests ECS dysfunction may be involved in the development or maintenance of compulsive behaviors, but more research is needed to understand the precise mechanisms. {“@context”: “https://schema.org”, “@type”: “ScholarlyArticle”, “headline”: “The Endocannabinoid System in Obsessive-Compulsive Disorder: A Scoping Review.”, “url”: “https://pubmed.ncbi.nlm.nih.gov/41871777/”, “about”: “neuroscience biobehavioral reviews clinical study endocannabinoid”, “isPartOf”: “Neuroscience and biobehavioral reviews”} [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Cannabis Use Disorder Treatment Europe Review](https://cedclinic.com/cannabis-use-disorder-treatment-europe-evidence-watch/) A comprehensive review of [cannabis use disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/) treatments in Europe, highlighting clinical evidence and treatment outcomes. [Read the Review](https://cedclinic.com/cannabis-use-disorder-treatment-europe-evidence-watch/) [Modulating the endocannabinoid system in alcohol use disorder](https://cedclinic.com/cbd-alcohol-use-disorder-treatment-research-systematic-review/) Systematic review and meta-analysis exploring ECS modulation effects in alcohol use disorder from preclinical and human studies. [Explore the Research](https://cedclinic.com/cbd-alcohol-use-disorder-treatment-research-systematic-review/) [Cannabinoids for Autism: Clinical Evidence Reviewed](https://cedclinic.com/therapeutic-cannabis-autism-systematic-review/) Review of clinical evidence on cannabinoids for autism spectrum disorder, discussing therapeutic potential and research gaps. [Learn More](https://cedclinic.com/therapeutic-cannabis-autism-systematic-review/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).